enVVeno Medical (NVNO) Projected to Post Earnings on Thursday

enVVeno Medical (NASDAQ:NVNO) is projected to post its results before the market opens on Thursday, February 26th. Analysts expect enVVeno Medical to post earnings of ($9.80) per share for the quarter.

enVVeno Medical Stock Up 1.9%

Shares of enVVeno Medical stock opened at $11.50 on Wednesday. enVVeno Medical has a 12-month low of $8.67 and a 12-month high of $196.70. The stock has a market capitalization of $7.59 million, a P/E ratio of -0.30 and a beta of 1.07. The stock has a 50 day moving average price of $11.14 and a two-hundred day moving average price of $26.41.

Institutional Investors Weigh In On enVVeno Medical

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in shares of enVVeno Medical during the 2nd quarter worth about $51,000. Creative Planning acquired a new stake in enVVeno Medical during the second quarter worth about $54,000. Geode Capital Management LLC grew its position in enVVeno Medical by 1.1% during the second quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock worth $796,000 after buying an additional 2,211 shares in the last quarter. Finally, Perceptive Advisors LLC bought a new position in enVVeno Medical during the second quarter valued at about $5,127,000. Institutional investors and hedge funds own 34.71% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of enVVeno Medical in a research note on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.

About enVVeno Medical

enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.